NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) is a broad topic spanning pharmacology, clinical use, and toxicity across multiple specialties. Rather than dump everything at once, here's a map of the territory:

1. Mechanism of action - COX-1 vs COX-2 inhibition, prostaglandin/thromboxane synthesis pathway, why this explains both efficacy and toxicity 2. Classification - Non-selective (ibuprofen, naproxen, diclofenac, indomethacin, aspirin) vs COX-2 selective (celecoxib, etoricoxib) 3. Clinical indications - Pain, inflammation, fever, antiplatelet effect (aspirin), specific uses in rheumatology (RA, osteoarthritis, gout), dysmenorrhea 4. GI toxicity - NSAID-induced ulcers/bleeding, mechanism, risk factors, prevention (PPIs, misoprostol) 5. Cardiovascular risk - COX-2 selective agents and MI/stroke risk, non-selective agents, aspirin's cardioprotective exception 6. Renal effects - Acute kidney injury, sodium/fluid retention, interaction with ACE inhibitors/diuretics ("triple whammy") 7. Other adverse effects - Hepatotoxicity, hypersensitivity/asthma (aspirin-exacerbated respiratory disease), hematologic effects 8. Drug interactions and contraindications - Anticoagulants, lithium, methotrexate; pregnancy, elderly, renal/hepatic impairment 9. Individual drug profiles - Specific pharmacokinetics/dosing of aspirin, ibuprofen, naproxen, diclofenac, indomethacin, ketorolac, celecoxib

Brief overview: NSAIDs work by inhibiting cyclooxygenase (COX-1 and/or COX-2) enzymes, blocking prostaglandin synthesis - this reduces pain, fever, and inflammation but also removes the protective prostaglandin effects on gastric mucosa and renal blood flow, which is the root of their two major toxicities (GI ulceration/bleeding and renal impairment). COX-2 selective agents were developed to reduce GI risk but carry increased cardiovascular risk instead. They are among the most widely used drug classes worldwide but require careful risk-benefit assessment, especially in the elderly, in renal/cardiac disease, and with concurrent anticoagulation.

Recent evidence flag: A 2026 systematic review (PMID 41230625) on cardiovascular risks and a 2026 meta-analysis (PMID 40915652) on GI bleeding risk with NSAIDs are available if you want current risk-quantification data rather than textbook-level generalities.

Which area do you want to go deep on?